Curis, Inc.
NASDAQ:CRIS
$4.79
$0.10
(2.13%)
Quote as of 4:00 PM EST on 02/14/12
|
$4.79
$0.10
(2.13%)
|
|
| Today's Open | $4.70 |
|---|---|
| Previous Close | $4.69 |
| Daily Range | $4.65 - $4.80 |
| 52-Week Range | $2.70 - $5.65 |
| Market Cap | $366.82M |
| P/E Ratio | -36.08 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 779,480 |
| Average Daily Volume | 893,269 |
| Current FY EPS | -$0.07 |
CRIS Information
| Description |
|---|
| A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Prized Bio Assets Come in Small Packages
Maximum Market: $2.9 Billion, For Now
This Just In: More Upgrades and Downgrades
This Drug Approval Is Good For the Industry
US FDA Approves Roche and Curis Skin Cancer Drug
UPDATE:FDA Approves Roche's Erivedge For Basal Cell Skin Cancer
In Drug Development, Help Is Crucial
Investing 101: Rallying Stocks Under $5 Undervalued to Analyst Estimates
UPDATE: Roche 'Hedgehog Inhibitor' Shrinks Basal Cancer Tumors -Study
Best Performing U.S. Stocks Year to Date
